| abstract |
Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders. Specifically, this application relates to novel compounds comprising anti-DLL3 antibodies or immunoreactive fragments thereof having one or more unpaired cysteine residues conjugated to pyrrolobenzodiazepines (PBDs) and use of the same for the treatment or prophylaxis of cancer and any recurrence or metastasis thereof. |